미국, EU4(독일, 프랑스, 이탈리아, 스페인), 영국, 일본의 수용체 상호작용 단백질 키나아제1(RIPK1) 억제제(Receptor Interaction Protein Kinase 1(RIPK1) 억제제) 시장 배경, 경쟁 구도, 시장 동향에 대해 상세하게 조사 분석하였습니다.
세계 7개국(미국, EU4, 영국, 일본, 중국, 일본)의 7MM 치료 실태, 신규 치료제 동향, 각 치료제별 시장 점유율, 2021년부터 2034년까지 시장 규모 현황과 예측에 대해 조사 분석하여 전해드립니다. 또한, 미충족 의료 수요에 대해서도 다루어 시장의 잠재력을 평가하고 최적의 사업 기회를 파악할 수 있는 내용으로 구성되어 있습니다.
조사 기간: 2021-2034년
DelveInsight's "Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors - Target Population, Competitive Landscape, and Market Forecast - 2034" report delivers an in-depth understanding of the RIPK1 inhibitors, historical and competitive landscape as well as its market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The RIPK1 inhibitors' market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM RIPK1 inhibitors' market size from 2020 to 2034. The report also covers current RIPK1 inhibitors' treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.
Study Period: 2020-2034
Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Overview
Receptor-Interacting Protein Kinase 1 (RIPK1), a key member of the RIPK protein family, serves as a central mediator of both cell death and inflammatory responses, thereby playing a vital role in sustaining cellular and tissue equilibrium. RIPK1's kinase activity is particularly important in orchestrating necroptosis-a programmed form of necrotic cell death-as well as Tumor Necrosis Factor (TNF)-induced necrosis. Consequently, RIPK1 has gained recognition as a pivotal upstream regulator involved in several signaling pathways that govern inflammation and cell survival. Notably, RIPK1 is expressed across all major cell types within the Central Nervous System (CNS). Targeted inhibition of RIPK1 has demonstrated the ability to protect neurons from cell death, offering potential therapeutic benefits by reducing both neurodegeneration and neuroinflammation. Moreover, the structural characteristics of RIPK1's kinase domain make it an attractive target for the development of selective small-molecule inhibitors.
Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Market Overview
In recent years, there has been a growing interest in the exploration of RIPK1 inhibitors for a variety disorders, encompassing rheumatoid arthritis, ulcerative colitis, and other indications.
The epidemiology chapter RIPK1 inhibitors in the report provides historical as well as forecasted epidemiology segmented as total cases in selected indications for RIPK1 inhibitors, total eligible patient pool in selected indications for RIPK1 inhibitors, and total treated cases in selected indications for RIPK1 inhibitors in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.
The drug chapter segment of the RIPK1 inhibitors report encloses a detailed analysis of early and mid-stage RIPK1 inhibitors. It also helps understand the clinical trial details of RIPK1 inhibitors, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Emerging Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors
Ocadusertib (R552/LY3871801): Rigel Pharmaceuticals and Eli Lilly
Ocadusertib, a small molecule being developed for the treatment of autoimmune and inflammatory disorders, and brain penetrating RIPK1 inhibitors for CNS diseases. In preclinical studies, R552 demonstrated prevention of joint and skin inflammation in a RIPK1-mediated murine model of inflammation and tissue damage. The comapny had initiated a Phase IIa clinical trial (NCT05848258) studying ocadusertib in adult patients with moderately to severely active rheumatoid arthritis. Pursuant to the collaboration, Eli Lilly will also lead all clinical development of brain penetrating RIPK1 inhibitors in CNS diseases (Alzheimer's disease and amyotrophic lateral sclerosis [ALS]). RIPK1 inhibitors play key role in TNF signaling and induction of pro-inflammatory necroptosis, which could support broad potential in rheumatoid arthritis, psoriasis and IBD, and with their experience, Lilly is the ideal partner for Rigel Pharmaceuticals.
In its 2024 annual presentation, the company stated that enrollment for the Phase IIa trial involving approximately 100 patients is ongoing and preliminary results are expected in the first half of 2025.
Eclitasertib (SAR443122/DNL758): Sanofi and Denali Therapeutics
Eclitasertib (SAR443122), a small-molecule inhibitor of RIPK1, is being co-developed in partnership with Denali Therapeutics. The ongoing Phase II RESOLUTE study is currently evaluating its efficacy in patients with moderate to severe ulcerative colitis.
The global RIPK1 inhibitor market is expected to witness substantial growth in the coming years, driven by the increasing prevalence of autoimmune diseases, robust clinical pipeline activity, and expanding regulatory approvals.
Several leading companies, including Rigel Pharmaceuticals, Eli Lilly, Sanofi, and Denali Therapeutics, are actively involved in the development of RIPK1 inhibitors for a range of indications such as rheumatoid arthritis, ulcerative colitis, and others. Early-stage clinical trials have also explored RIPK1 inhibitors for conditions like Cutaneous Lupus Erythematosus (CLE), Acute Graft versus Host Disease (aGvHD), Alzheimer's disease, ALS, plaque psoriasis, and multiple sclerosis. However, many of these programs were discontinued and kept on hold in early phases due to safety issues, limited efficacy, or shifting strategic priorities.
ABBV-668, AbbVie's small molecule RIPK1 inhibitor, was under investigation for ulcerative colitis. As per the clinicaltrials.gov ABBV-668 has completed its Phase II trial in ulcerative colitis as of December 2024, while there is no update regarding its clinical development since then and the product is not present in the pipeline.
In addition, several studies on RIPK1 inhibitors have been conducted outside the 7MM. For instance, AC-003 by Accro Biosciences is currently in a Phase Ib clinical trial for patients with aGvHD and is also under investigation for Idiopathic Pulmonary Fibrosis in China. Furthermore, SIRONAX is developing SIR9900 and SIR2446 for the treatment of neurodegenerative, immune, and inflammatory disorders. First-in-human, Phase I study to evaluate SIR9900 was conducted in Australia (Nucleus Network Pty Ltd. Melbourne, Australia) to evaluate the safety and tolerability of single ascending doses (SAD) and multiple ascending doses (MAD) of oral SIR9900 in healthy adult and elderly participants.
Overall, this is an exciting new class with great potential for development. The maturation of current studies over the next few years will lead to a better understanding of RIPK1 inhibitors and define their role in autoimmune indications.
This section focuses on the uptake rate of potential approved and emerging RIPK1 inhibitors expected to be launched in the market during 2025-2034.
Receptor-interacting Protein Kinase 1 (RIPK1) Inhibitors Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II and Phase I. It also analyzes key players involved in developing targeted therapeutics.
The presence of numerous drugs under different stages is expected to generate immense opportunity for RIPK1 inhibitors market growth over the forecast period.
Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for RIPK1 inhibitor therapies.
KOL Views
To keep up with current and future market trends, we take Industry Experts' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on RIPK1 inhibitors' evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along challenges related to accessibility.
DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as Duke University School of Medicine, and others.
Their opinion helps understand and validate current and emerging therapy treatment patterns or RIPK1 inhibitors' market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Market Access and Reimbursement
Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health Technology Assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug.
In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Continuing Medical Education (CME) program, the Children's Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third-party organizations that provide services, and educational programs to aid patients are also present.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
The abstract list is not exhaustive, will be provided in the final report